Sep 7, 2017

Drugs don't work if people can't afford them

From our Expert Voices conversation on drug pricing.

American citizens help fund the basic science behind most drugs, and then we give corporations monopoly power to set the prices at whatever the market will bear. 50-60% of all new drugs are based on research funded by U.S. taxpayers and currently, we pay twice as much for most drugs as people in other wealthy nations.

Drug companies have a responsibility to:

  • Acknowledge taxpayers' investment and explain how the price of a drug reflects that investment.
  • Publicly commit that when a drug is approved in other countries, U.S. taxpayers will not be charged more than citizens of other wealthy nations given America's unique investment into the science driving drug discoveries.
  • Explain how the price of an orphan drug for treating rare diseases will decline as the number of patients receiving the drug expands.

The bottom line: Novartis's new CAR-T drug, Kymriah, is an incredibly important one. But American taxpayers invested over $200 million in CAR-T's discovery. Based on several different data points, we believe the price for Kymriah is about $125,000-150,000 too high. That's disappointing. Drugs don't work if people can't afford them.

Other voices in the conversation:

Go deeper

Private equity returns fell behind stocks over the past decade

Illustration: Aïda Amer/Axios

U.S. private equity returns fell just below S&P 500 returns for the 10-year period ending last June, according to a report released Monday morning by Bain & Company.

Why it matters: Private equity markets itself as beating public markets over long-term time horizons, and usually providing an illiquidity premium to boot. These new performance figures not only dent such claims, but provide fresh ammunition to critics of public pension investment in private equity funds.

Why Apple may move to open iOS

Photo illustration: Jakub Porzycki/NurPhoto via Getty Images

Apple may finally allow iPhone owners to set email or browsing apps other than Apple's own as their preferred defaults, according to a Bloomberg report from last week.

The big picture: Customers have long clamored for the ability to choose their preferred apps, and now Apple, like other big tech companies, finds itself under increased scrutiny over anything perceived as anticompetitive.